Clinical Trial Update: Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Ivonescimab in combination with FOLFOX for advanced HER2-negative gastroesophageal cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Ivonescimab (AK112/SMT112)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Stomach Cancer Stage IV, Esophagus Cancer | Phase 2 | Status: RECRUITING